Home › Compare › MSPAF vs ABBV
MSPAF yields 33.78% · ABBV yields 3.06%● Live data
📍 MSPAF pulled ahead of the other in Year 1
Combined, MSPAF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MSPAF + ABBV for your $10,000?
Growens S.p.A., together with its subsidiaries, engages in the cloud marketing technology business in Italy, other European countries, the Americas, and Asia. It operates through E-mail Marketing, Mobile Marketing/Messaging, and Marketing Automation Segments. The company is involved in the development and sale of technologies for the mass sending of e-mails and mobile messaging through the SMS channel for marketing and transaction purposes. It also provides e-mail and newsletter editing tools; marketing technology solutions; and professional consulting services. In addition, the company offers MailUp, a platform that offers data presentation tools, including statistics for engagement that presents statistical data to help users enhance the effectiveness of their campaigns through e-mail and then to take corrective actions to enhance the performance of future campaigns, as well as the multi-list dashboard feature, which is a summary tool to have an immediate overview of the progress of campaigns. Further, it provides BEE, a drag-and-drop editor for e-mails and landing pages; Acumbamail, a Spanish e-mail marketing platform, which allows the creation, sending, and management of multi-channel marketing campaign; and Datatrics platform, which allows the marketing teams to build experiences based on data managed by artificial intelligence. The company was formerly known as Mailup S.p.A. and changed its name to Growens S.p.A. in April 2021. Growens S.p.A. was founded in 2002 and is headquartered in Milan, Italy.
Full MSPAF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.